LexaGene Positioned to Fight Coronavirus Pandemic

by | Mar 27, 2020 | Human Clinical Diagnostics

Home » Human Clinical Diagnostics » LexaGene Positioned to Fight Coronavirus Pandemic

Forbes profile on LexaGene’s technology:

‘It’s hard to imagine a startup better positioned to respond to the coronavirus pandemic than Beverly, Massachusetts-based LexaGene.’

Read the Full Article Here
<a href="https://lexagene.com/author/lexagene-admin/" target="_self">LexaGene</a>

LexaGene

LexaGene develops fully automated, rapid molecular testing at the point-of-need for accurate pathogen detection in human clinical diagnostics, veterinary diagnostics, food safety, and other markets.

Survey Says Veterinarians Have an Appetite for In-Clinic Diagnostic Technology

This spring LexaGene conducted a market research survey in conjunction with AAHA to assess the opinions of practicing veterinarians on AMR stewardship and the use of antibiotics in the treatment of companion animals.

The Dawn of the Superbugs

The most menacing of all resistant bacteria are the so called “super bugs”- strains of bacteria that are resistant to several different classes of antibiotics or multidrug resistant.

LexaGene offers North Shore Technology Council (NSTC) and Leadership Team at MassBio a tour of our Beverly Facility

Recently, we welcomed members of North Shore Technology Council and MassBio Leadership Teams into our facility at 500 Cummings Center for a full tour of our office space and laboratory spaces.

Upcoming Events

BioFuture

NYC
October 05, 2021 - October 06, 2021
The in-person and virtual event held in New York City attracted more than 550 attendees, including 100 speakers sharing their expertise, insight, and predictions.

Latest Resources

Sorry, we don't have any content in this category with that format. Is there anything we can help you with?